Related Experiment Video
Updated: Jun 20, 2026
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Antigen Spreading via Localized Administration Enhances Adoptive TCR-T Cell Therapy in Pancreatic Cancer
Junming Huang1,2, Qin Wang1,2, Zhuo Yao1,2
1Department of Hepatobiliary and Pancreatic Surgery, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Abstract:
Cancer vaccines have demonstrated initial effectiveness in the treatment of human cancers, still the low mutational burden, which leads to a deficiency of well-characterized antigens expressed within tumors capable of mediating tumor rejection, poses a significant challenge in pancreatic cancer. Here, we introduce an ionic liquid ILvax for localized tumor administration, which elicits a systemic and antigen-specific anti-tumor immune response, thereby generating a vaccine-like effect. Type 1 conventional dendritic cells (cDC1) is the determinant for systemic immune response. ILvax ablation facilitates migration of tumor antigen-carrying cDC1 to peripheral lymphoid organs, thus initiating the cDC1-mediated antigen presentation cascade that results in an amplified antigen-specific T cells response. Meanwhile, cDC1-mediated antigen spreading induced by ILvax enabled the expansion of adoptive TCR-T while shifting TCR-T metabolism toward oxidative phosphorylation (OXPHOS). Localized tumor administration with ILvax simultaneously enhances the functionality of both endogenous CD8+ T cells and adoptive TCR-T cells, offering a clinically translatable collaborative strategy against pancreatic cancer.
Insights
A novel ionic liquid, ILvax, acts as a cancer vaccine for pancreatic cancer by enhancing T cell responses. ILvax promotes antigen presentation and T cell expansion, offering a promising therapeutic strategy.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Pancreatic cancer presents a significant challenge due to low mutational burden and limited tumor antigens for rejection.
- Existing cancer vaccines face hurdles in eliciting effective anti-tumor immunity in pancreatic cancer.
Purpose of the Study:
- To introduce ILvax, an ionic liquid formulation for localized tumor administration.
- To investigate ILvax's capacity to elicit a systemic, antigen-specific anti-tumor immune response.
- To evaluate ILvax's potential as a vaccine-like therapy for pancreatic cancer.
Main Methods:
- Localized tumor administration of ILvax.
- Analysis of Type 1 conventional dendritic cell (cDC1) migration and function.
- Assessment of antigen presentation cascade and T cell responses (endogenous CD8+ T cells and adoptive TCR-T cells).
- Evaluation of TCR-T cell metabolism shift towards oxidative phosphorylation (OXPHOS).
Main Results:
- ILvax elicits a systemic and antigen-specific anti-tumor immune response.
- ILvax facilitates cDC1 migration, enhancing antigen presentation and amplifying antigen-specific T cell responses.
- ILvax promotes antigen spreading, leading to expansion of adoptive TCR-T cells and a metabolic shift towards OXPHOS.
- Localized ILvax administration enhances both endogenous CD8+ T cells and adoptive TCR-T cells.
Conclusions:
- ILvax demonstrates a vaccine-like effect by generating a robust systemic anti-tumor immune response.
- ILvax represents a clinically translatable collaborative strategy for enhancing immunotherapy in pancreatic cancer.
- The study highlights the critical role of cDC1s in ILvax-mediated anti-tumor immunity.
Related Concept Videos
01:27Tumor Immunotherapy
01:40Cell-mediated Immune Responses